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The ultimate goal of radiotherapy for cancer is to eradicate the tumor growth 
while minimizing the impact on normal tissue. Compared to x-ray therapy, 
particle beam therapy offers distinct advantages due to the inverse dose profile. 
The energy deposited along the incoming beam is much reduced compared to x-
rays, and virtually no dose is deposited by particle beams beyond the Bragg peak. 
From the very beginning in 1946 heavy ions were studied in parallel to protons 
because of the enhanced biological effectiveness, and currently one can observe a 
strong increase of interest in heavy charged particle therapy, especially in Europe. 
For similar reasons other, more exotic, particles have been considered for therapy. 
Pions were studied extensively in the 60’s and 70’s but eventually abandoned due 
to the poor dose conformity and the contamination of the beam by decay products. 
Antiprotons have been proposed on theoretical grounds by Kalogeropoulos and 
Gray [1] in 1984. Shortly afterwards it has been shown by Sullivan [2] that the 
physical dose deposition at the end of range is twice that obtained for protons. 
Clearly, for all particles considered the simple picture of dose deposition due 
to the primary beam needs to be augmented by inclusion of secondary particles 
due to nuclear interactions between beam and target atoms. These not only can 
cause a modification of the dose profile in the target but also will deposit dose 
outside the targeted volume. Spectral and geometrical distributions of secondary 
particles will vary with type of primary particle and complex dose planning tools 
are being developed to take these effects into account. Due to longer survival 
times achievable today late effects and secondary cancers caused by the initial 
therapy are becoming more and more a concern in clinical practice and several 
large reviews in this field have been published in the last year [3]. 
In 2003 the AD-4 experiment was initiated to study the biological 
effectiveness of antiprotons with a focus on potential use in cancer therapy. In 
addition to the increased physical dose available when using antiprotons it has 
been postulated that the biological effectiveness in the Bragg peak should be 
enhanced, as a significant part of the additional energy is deposited by heavy ion 
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recoils and nuclear fragments. An additional advantage already mentioned by 
Kalogeropoulos et al. consists in the possibility of real-time monitoring of the 
actual dose deposition.  
A significant concern in antiproton therapy could be the secondary dose due to 
medium and long-range products of the annihilation events, high-energy pions and 
gammas, as well as neutrons with a broad energy spectrum.  To perform a 
balanced assessment of the potential of antiprotons for cancer therapy detailed 
knowledge of physical energy deposition, biological efficiency in the primary 
beam path, and a full understanding of the mixed radiation field produced by the 
annihilation events is necessary.   
The AD-4/ACE collaboration has been studying the biological effects of 
antiproton beams on living cells for an integrated beam time of 6 weeks since 
2003. Initial experiments using a beam at 46.7 MeV kinetic energy readily 
available at CERN did show a significant enhancement of the biological effective 
dose ratio (BEDR) for antiprotons compared to protons. The experimental 
methods and analysis as well as the definition of terms used here are described by 
Holzscheiter et al. [4]. Based on this initial success the collaboration requested 
delivery of a higher energy beam (502 MeV/c), providing deeper penetration into 
the target and allowing the use of a clinically relevant spread-out Bragg peak 
(SOBP). We have used this beam setting for four run periods and have collected 
data on dosimetry of the mixed radiation field produced by the annihilation of 
antiprotons as well as on cell survival of V79 Chinese Hamster cells and Human 
FaDu cells (a human epithelial cell line derived from a squamous cell carcinoma 
of the hypopharynx). 
Using dosimetric measurements with ionization chambers and alanine pellets 
we have successfully benchmarked the FLUKA Monte Carlo code [5], which now 
allows precise dose planning of the irradiation experiments. Using the calculated 
dose values along the beam path together with reference measurements using the 
same materials and methods and a standard 60Co radiation source we can now 
extract the Relative Biological Efficiency (RBE) instead of using the Biological 
Effective Dose Ratio (BEDR) utilized in the initial experiments. RBE, while still a 
complex quantity and dependent on a variety of physical and biological 
parameters, can be compared more easily across different radiation modalities and 
can be used to analyze the differences in therapeutic potentials for different 
radiation qualities.  
Early 2007 we also performed a set of irradiations using the same methods and 
materials at GSI with carbon ions giving the same calculated penetration depth 
and the same calculated width of the Spread Out Bragg Peak (SOBP) as the 
antiprotons at CERN.  
We have published a number of papers describing the results of the cell 
survival measurements and the progress on dosimetry and Monte Carlo (see 
Appendix I). While a continuation of cell survival measurements is necessary to 
base any assessment of the therapeutic potential of antiprotons and any 
comparison to other particle beam modalities on a well-founded scientific basis, 
the collaboration has initiated in parallel work on studying potential detrimental 
effects on cells placed outside the primary beam area (peripheral effects). 
Measurements of cell survival beyond the Bragg peak can be used for an initial 
assessment of the relevance or severity of these effects, but as the relevant 
biological endpoint in this context is not tumour control but normal tissue 
complication, other methods that are sensitive to DNA damage on the cellular 
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level seem more appropriate. Original experiments using a combination of 
clonogenic survival and the COMET assay to study the incidence of DNA double 
strand breaks hinted that the out-of-field effects are small [6]. In 2008 we 
performed a pilot study on the development of foci using the γ-H2ΑX assay, and 
based on preliminary results we designed an improved experiment concentrating 
on a systematic study of cell damage outside the direct beam due to medium and 
long-range secondary products from the annihilation events. In parallel, these 
studies were also designed to obtain information on the chemically mediated 
bystander effect where cells not subject to irradiation show effects due to the 
irradiation of cells with which they share medium; they are bystanders to the 
irradiation.  
In addition to biological studies we have dedicated a moderate percentage of 
the available beam time to the development of beam monitor systems and novel 
dosimetric methods that promise direct measurements of linear energy transfer 
(LET) in the beam. These methods are not restricted in use to antiprotons but 
would represent important tools for heavy ion therapy, where RBE variations 
along the primary beam and within the spread-out Bragg peak (SOBP) are present 
as well. 
Parallel, and completely symbiotic, we have increased our efforts towards real 
time imaging of the stopping distribution. We have performed a Monte Carlo 
study [7] showing that the very initial fraction of a typical treatment delivered 
with antiprotons would be sufficient to obtain a high-resolution image of the 
actual dose deposition. This would be an invaluable tool to any clinician who 
faces the uncertainties in depth dose profiles due to inhomogeneities in the target 
and uncertainties in ionization potential for the complex target materials 
encountered. Using a silicon pixel detector provided to us by the ALICE 
collaboration we have obtained first promising experimental results on a simple 
detector arrangement. 
Initial Monte Carlo calculations for realistic treatment situations have been 
performed, based on physical dose alone [8]. Based on these results and a 
simplified model on RBE variation vs. depth for antiprotons and carbon ions we 
have generated generic comparisons between protons, antiprotons, and carbon 
ions. Using independent optimization of the dose plan for each particle type we 
have shown that antiprotons not only show a clear improvement compared to 
protons in terms of secondary dose outside the target volume but also may be 
superior to carbon ions in terms of medium dose deposition outside the target. 
This is of interest as some recent studies point exactly towards this dose range in 
the context of secondary primary malignancies due to radiotherapy [3].  
Putting aside any economic constraints, our current results indicate that 
antiprotons could be a serious contender for radiotherapy of specific tumor 
incidents. More work is needed to fully understand the biological effects outside 
the primary target as well as the tumor control possibility under different 
conditions. To identify those cases that would show a true benefit of antiprotons 
compared to protons or heavy ions biological models need to be modified to 
incorporate the complex radiation field generated by antiproton annihilations. For 
this more data on cell survival, DNA damage, and the effect of oxygen 
enhancement ratios (OER) will be needed from carefully designed benchmark 
experiments. These data can then be linked to the large body of biological data 
available in the literature from proton, carbon ion, pion, and neutron therapy 
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studies. Only then a final assessment of antiproton cancer therapy can be 
completed. 
Our work is directly linked to the development and advancement of carbon ion 
therapy and we are closely collaborating with several groups active in this field. 
While we benefit significantly from the work on biological modeling and detector 
response to complex radiation fields, many of our technological developments 





The overall goal of the AD-4 Experiment is to study the biological effect of 
antiprotons in order to validate earlier theoretical predictions that antiprotons 
could produce a better therapeutic ratio for the treatment of well defined tumors. 
This prediction is based on two observations: 
 
1. The physical dose should be augmented near the end of range due to the 
additional energy deposited locally when antiprotons annihilate.  
2. Some of the additional energy deposited results from low energy heavy ion 
recoils produced in the annihilation event, which are expected to exhibit a 
higher biological efficiency.  
 
To quantify these observations several studies are needed. One is a detailed 
measurement of the dose deposition of an antiproton beam of a specific energy 
entering a biological target, which then can be compared to Monte Carlo 
calculations and can be used to benchmark different available codes. The second 
piece of information needed is the relative biological effect with respect to a 
standard radiation type (typically a 60Co source) along the path of the antiproton 
beam, preferably for a number of different cell lines extensively used in cancer 
research. Once these two questions are answered one can then use these results as 
input data for treatment planning tools and develop comparative treatment plans 
for a specific tumor for antiprotons, carbon ions, and protons. Based on these 
plans one can determine specific incidences of cancer where antiprotons could 
provide a significant benefit to patients.  
Since antiproton annihilation also yields a significant component of medium 
and high-energy secondary particles, which will leave the annihilation vertex, a 
third, very critical issue to be studied is the biological effect of this background on 
cells outside the direct target area. 
 
 




In 2006, 2007, 2008, and 2009 we were assigned 1 week each of antiproton 
beam time, using a special extraction method providing a beam of 502 MeV/c 
antiprotons. As this extraction method is sufficiently different from normal AD 
operation it was decided to lump all beam time into a single run of 7 days of 24 
hours. Typically, the first two to three days of the week are needed for beam set-
up and dosimetry studies. Only when the desired beam quality is achieved, the 
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biological measurements can be initiated. As cell viability in the gelatin medium 
used is limited to 48 – 72 hours, this has to be orchestrated precisely and we 
typically allow some extra time before the start of biological measurements which 
always was (in case that set-up of the beam was completed faster) used 
beneficially for physics studies of dosimetry systems, beam monitors, and to 
collect dose data for Monte Carlo benchmarking.  
The 502 MeV/c antiproton beam from the AD provides a penetration into our 
target of approximately 10 cm. We use a set of passive degraders to generate a 
spread-out Bragg peak of 10 mm depth, irradiating a volume of approximately 
300 mm3. This is much more closely resembling possible therapeutic situations 
encountered in realistic treatment scenarios than what was possible with the 300 
MeV/c beam available before 2006. It also allows a much clearer separation 
between the entrance channel, where we expect low LET (and thereby low RBE) 
to dominate from the high LET/RBE region around the end of range. A typical 









0 20 40 60 80 100 120 140















Fig. 1: Typical depth dose profile for antiprotons obtained from FLUKA (normalized to 1 Gy 
plateau dose). 
 
In addition to the antiproton experiments at CERN we performed a 
comparison measurement using carbon ions at the heavy ion therapy unit at GSI in 
Darmstadt, Germany and a number of low LET calibration measurements needed 
for RBE analysis, which were performed at the German Cancer Research Center 
or at the Aarhus University Hospital. For the carbon ion measurements a spread-
out Bragg Peak identical to the one shown above for antiprotons was programmed 
into the beam delivery software of the GSI treatment system.  
 
Carbon Ion Measurements 
 
In order to compare our studies with antiprotons to the gold standard of high 
LET particle therapy an experiment using carbon ions was conducted in early 
2007 at GSI. Here a beam of clinical quality and absolute dosimetry was available 
and irradiations of 8 samples with plateau dose values between 0.3 and 4.0 Gy 
were performed. Survival data vs. depth are shown in figure 2. 
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Figure 3 shows the results of our analysis for the carbon ion experiment. 
Defining the plateau as data points 1 and 2 and the peak as points 9 – 14 of the 
depth survival curve (figure 2) we can plot survival vs. absolute dose for peak and 
plateau. In addition we plot survival vs. dose for a reference X-ray source with 
low LET and a RBE of 1. Using a biological endpoint of a survival rate of 10% 




Figure 2: Survival fraction vs. depth in the target for V79 Chinese Hamster cells irradiated 
with carbon ions 
 
 




Figure 3: Survival fraction vs. absolute dose for V79 Chinese Hamster cells irradiated with 
carbon ions. By comparing the dose needed to achieve a survival of 10% using low LET X-
rays to the dose needed when using carbon ions we extract a relative biological efficiency of 
1.38 in the plateau and 2.17 in the peak. 
 
 
Antiproton Measurements – V79 Chinese Hamster Cells 
 
In 2006 we performed 4 different irradiations with nominal dose values of 
0.25, 0.5, 1, and 5 Gy. Due to high uncertainties in estimating the absolute dose, 
only the lowest three dose values yielded useful data. For the 2007 run period we 
had improved our dosimetry capabilities and were able to control the absolute 
dose delivered to the target to within 10%, allowing us to augment above data 
sets. We performed irradiations on V79 cells for 6 different dose values. These 
dose values were selected using FLUKA based on dosimetric information 
obtained before the irradiation together with a best guess for the dose response 
curve based on previous measurements to achieve specific desired survival values 
in the peak and/or plateau region. Dosimetric control measurements between 
different badges were performed to assure the stability of the beam delivery 
system. The raw data obtained in 2007 are shown in figure 4 below. A final 
problem apparent from these data is the fact that we still failed to produce a flat 
response to the radiation within the spread-out Bragg peak. This was essentially 
due to the fact that we used pre-calculated kernels for the depth dose curve, which 
then were shifted according to additional degrader thickness, a method widely 
used in radiotherapy planning. This does not include the effect of additional lateral 
scattering, which dilutes the beam intensities for thicker degrader settings and a 
full Monte Carlo calculation was necessary to overcome this problem. (Note: this 
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problem is specific to the beam conditions here as the beam is too narrow to 




Fig. 4: Survival fraction vs. depth in the target for V79 Chinese Hamster cells irradiated with 
antiprotons. The dose values for the individual runs were estimated from FLUKA calculations 
using the number of antiprotons delivered and the radial beam profile obtained from 





Figure 5 shows the raw data from the October 2008 data run where we  
achieve a Spread-Out Bragg Peak with a flat peak region. Also, the sensitivity of 
the clonogenic assay could be further improved and we are now able to measure 
survival fractions as low as 1 x 10-4. 
 




Fig. 5: Survival fraction vs. depth in the target for V79 Chinese Hamster cells irradiated with 
antiprotons during the 2008 run period. 
 
 
In 2009 we continued these measurements with a focus on obtaining 
statistically significant data distal to the Bragg peak. After taking a few low dose 
runs to establish the exact position of the survival curve we then took long 
irradiation periods to achieve plateau doses of nominally 18 and 23.5 Gy. But 
even at these high dose levels the survival returned to values of 50% and higher 
2 mm past the distal edge of the Bragg peak (100 mm). The slice at 102 mm is the 
only one yielding a large enough data spread to achieve a realistic fit of the linear-
quadratic dose response curve to the data. From this one fit we conclude that the 
RBE is already returning towards the plateau value. We are currently working on 
implementing a more robust fitting routine including constraints on the parameters 
alpha and beta of the linear quadratic model commonly used to describe the 
survival vs. dose response, and allowing to make the plating efficiency (survival 
at dose equal to zero) a free parameter. This would allow to correct for slice-to- 
slice variation of cells being plated due to volume effects. Analysis of these data is 
ongoing and we therefore refrain from including data plots on the distal edge RBE 
in this report. 
We used the data sets from 2007, 2008, and 2009 to analyse the dose response 
in the plateau region. Figure 6 shows the survival data from the three years 
together with a combined fit to all data and a dose response curve measured with 
60Co at Heidelberg after the 2008 run period. Using the dose values yielding a 
survival of 10% for both the fit to the data and the cobalt measurements we 
deduce a value for the RBEplateau = 1.25. While this value is well aligned with 
results of Monte Carlo studies performed by our group [9] the scatter of the data is 
still too large to quote this value as a final result.  




Fig. 6: Survival fraction vs. dose in the plateau region for V79 Chinese Hamster cells 
irradiated with antiprotons. For comparison the survival vs. dose for 60Co irradiation is 
shown. From these results an RBE in the plateau for 10% clonogenic survival of 1.25 is 
obtained. 
 
We are currently discussing changes to both the experimental protocol and the 
data fitting routine to improve this situation, but ultimately we need to 
experimentally establish error bars needed for proper weighting of the data in the 
fit. We also need more data points per slice as it is nearly impossible to fit 3 
parameters to just 4 - 5 data points and place any level of confidence on the result. 
As the errors are not purely statistical but are due to variations in cell preparation, 
plating, and response it is established practice in radiotherapy to repeat 
experiments several times and then use the standard deviation of the entire sample 
as error bar. To do this we need to assure that we get survival data in independent 
experiments at the same dose point. For the plateau region this is relatively easy as 
small shifts in dose value can be corrected since the RBE in the plateau is 
constant. It is a much more difficult task in the peak region, where we 
superimpose Bragg peaks with different ranges, so that at each depth point a given 
dose value can consist of different mixtures of RBE values and therefore yield a 
different survival value for the same depth and dose point, dependent on the 
detailed set-up of the experiment. To achieve this we need to have a much more 
stringent control on beam intensity and position fluctuations in order to produce 
identical situations in independent experiments. This is the primary reason for us 
to develop a new beam monitoring system to allow shot to shot analysis of shape, 
intensity, and position of each extracted AD pulse (see section VI).  
For illustration purposes only we show in figure 7 the dose response for the 
most distal position of the Bragg peak from 2008 in comparison to the plateau and 
cobalt data (for clarity we eliminated the individual data points in the plateau from 
the plot). The much reduced curvature of the survival curve is an indication for the 
increased LET and RBE in this region and the 10% survival extracted from this 
plot for RBE10%,peak is 2.25, 1.8 times higher than for the plateau. 





Fig. 7: Surviving fraction vs. dose for V-79 cells irradiated by 60Co, plateau antiprotons, and 
antiprotons in the distal edge of the Spread-Out Bragg Peak. RBE values quoted are for 10% 
clonogenic survival. The black and blue curves are identical to figure 6. 
 
 
To illustrate the significance of these results we performed a Monte Carlo 
Study [10] where a 2 x 2 x 2 cm3 target volume was irradiated with protons, 
carbon ions, and antiprotons. For each modality the constraint was set to the ICRU 
condition [11] that 95% of the target volume need to receive between 95% and 
105% of the prescribed target dose. To achieve the best target coverage with the 
steepest dose gradient at the target boundary we individually optimized the 
incoming beams using lateral and energy weighting.  
The results for both a single field and two opposing fields are shown in 
figure 8. Antiprotons have the highest peak to plateau ratio, as it is expected from 
the additional energy from the annihilation process. However, no dose is 
deposited by the protons beyond the SOBP in contrast to both antiprotons and 
carbon ions. In addition, the dose distribution outside the PTV is essentially of 
isotropic nature for antiprotons, whereas the carbon ions show a clear directional 
component, coming from secondary particles generated in-flight. While the dose 
distal to the Bragg peak initially is higher for antiprotons than for carbon ions, the 
dose tail for carbon ions extends further out and overtakes the antiproton tail a few 
centimeters past the distal edge. 
A standard method to compare different modalities is to generate so-called 
dose-volume-histograms (DVH). Here the percentage of the volume of interest 
(VOI) receiving a specific dose level is plotted against the percentage of the target 
dose. For the prescribed target volume (PTV) this ideally should be a square 
function with 100% dose to 100% of the target volume and then a sudden drop to 
0.    
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Fig. 8: Optimized single and double field dose plans for protons, antiprotons, and carbon 
ions. Antiprotons present the lowest dose in the entrance channel, but only at the expense of 
an extended low dose halo. 
 
Figure 9 shows the DVH’s for the PTV, and the lateral, proximal, and distal 
VOI’s for a single field irradiation. To highlight the effect of the change in 
relative biological efficiency (RBE) between plateau and peak for antiprotons and 
carbon ions compared to protons, we did apply a hypothetical RBE ratio of 2 
between the PTV and the region outside the PTV for both carbon ions and 
antiprotons. For the proximal region both carbon ions and antiprotons show 
clearly a superior behavior compared to protons, with antiprotons leading over 
carbon ions. But in the case of antiprotons this comes at the expense of an 
increased medium and low dose to the areas lateral and distal to the PTV. For 
laterally weighted beams the distal and lateral VOIs would be identical for 
antiprotons if lateral straggling of the beam could be ignored. The size of this 
effect can be deduced from the difference in the distal and lateral VOI for the case 
of protons. In regions lateral and distal to the PTV we find a larger volume 
receiving low dose (below 30% of the prescribed dose) for antiprotons than for 
carbon ions and protons. 
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Fig. 9.: Biological dose-volume histograms for laterally optimized Fields, of the PTV 
and the 3 volumes of interest. Here a RBE ratio of 2 is assumed for antiprotons and 
Carbon ions, as described in the text. 
 
To investigate the dose background outside the target volume, which is 
considered to be a relevant measure for the probability of long term 
complications, including second primary malignancy, we generate the DVHs for 
the entire phantom minus the PTV including a margin of 4 mm. In figure 10 we 
show the DVHs for the case of two opposing, laterally weighted fields, including 
again a hypothetical RBE ratio of 2 (right frame). We observe that antiprotons and 
carbon ions present a much lower radiation load to the whole body than protons in 
the high dose region, with a slight additional advantage for antiprotons over 
carbon ions for doses above approximately 15% of the prescribed target dose (in 
the RBE weighted case).  
From our early observations on RBE the step function approach to RBE 
variation may be a good approximation in the case of antiprotons, but certainly is 
oversimplyfying the known RBE dependence vs. depth for carbon ions in favor of 
carbon ions. Future work will include more precise RBE vs. depth functions for 
both antiprotons and carbon ions.  
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Fig. 10. DVH (left) and Biological-DVH (right) for the entire phantom minus the 
PTV and a 4 mm margin, using two opposing fields. For the Biological-DVH we 
assume a 2 times higher RBE in the PTV for antiprotons and carbon ions. 
 
 




In order to accurately investigate the implications of antiproton irradiation of 
living cells, it is important to analyze genetic complications that may arise in cells 
in regions peripheral to the targeted volume and may cause tumorigenesis and 
thus cancer development in previously healthy tissue. This would lead to the 
development of secondary primary malignancies, possibly many years after the 
treatment. To assess the risk of this necessitates developing experimental methods 
that allow sensitive and accurate measurements of critical DNA lesions. 
Double strand DNA breaks (DSBs) are highly cytotoxic lesions which, if 
unrepaired or repaired incorrectly, can cause cell death or mutations in DNA of 
daughter cells [12]. As few as one DSB can cause cell death or genetic mutations 
leading to disregulation of cell growth and tumorigenesis.  
Radiotherapy employs ionizing radiation (IR) to cause lethal damage to cells. 
It is widely accepted that cellular DNA is the most critical target. Immediately 
following an insult on DNA, damage sensing proteins (e.g. 53BP1, ATM) are 
recruited to the site of damage.  This signals cell cycle arrest so that DNA repair 
can take place [13,14]. A key event in repair of a DSB is the phosphorylation of 
the histone H2AX necessary to unwind the DNA and allow repair proteins to 
access the DSB site. 
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The γ-H2AX is a very sensitive and specific immunocytochemical assay based 
on antibodies which recognize, and bind to, the phosphorylated H2AX histone as 
an accurate indicator of a DNA DSB. A secondary fluorescing antibody is then 
introduced to the cells which will bind to the primary antibody so the aggregate 
(or focus) around the DSB can be analyzed by fluorescence microscopy It has 
been shown [15] that there is an excellent 1:1 relationship between the number of 
γ-H2AX foci and the DSB induced. This assay is used frequently to investigate 
DNA damage induction by heat shock, chemotherapeutic agents, ionizing 
radiation, bystander signaling and other DNA damage agents. 
In addition to direct damage from IR, there is mounting evidence for the 
existence of a non-targeted effect in which non-irradiated cells respond to the 
damage of their neighbours. This effect is known as the radiation induced 
bystander effect (RIBE) and it has been demonstrated in vitro for a number of 
endpoints including clonogenic survival, histone H2AX phosphorylation (γ-
H2AX) and genetic instability. There are also a number of in vivo studies showing 
these effects in mice. It is likely that RIBEs may contribute to the clinical 
appearance of abscopal effects following radiotherapy [15-17]. 
The aim of our study is to quantify the individual contributions of antiproton 
annihilation, secondary dose (neutrons, pions etc), and bystander signalling 
caused in live cells exposed to an antiproton beam. The study has a particular 
focus on the impact outside of the target volume in terms of cell viability and 
genomic integrity. The γ-H2AX and micronucleus assays have been used to study 
immediate and longer term DNA damage respectively.  
A pilot study at CERN in October 2008 demonstrated the applicability of this 
type of assay to studying antiproton induced DNA damage. These early 
experiments highlighted a number of issues: dose rate effects; contamination; the 
importance of cell culture facilities at or near CERN to obtain significant 
information from the samples (Problems highlighted in last year’s report). Each of 





Slide flasks containing cell samples were mounted within a phantom in 
specially designed holders. These were positioned at depths of 20 mm (plateau) 
and 101 mm (centre of SOBP) (fig.11b). Cell samples were irradiated horizontally 
in an open water phantom with circulating water-glycerine mixture maintained at 
4 ºC. Cells received estimated Bragg peak doses of 0.5, 0.75, 1.0, 2.0 and 5.0 Gy 
antiprotons.  
In addition to irradiated samples there were three sets of unirradiated samples: 
1) bystander cells (otherwise treated same as irradiated cells) were incubated at 37 
ºC for 1 h with filtered media from SOBP directly irradiated sample, 2) cold 
controls which were otherwise treated the same as irradiated samples, 3) warm 
controls which remained incubating at 37 ºC in the lab and were fixed along with 





























Fig.11. Experimental set-up for DNA damage experiments in 2009. Cells were seeded for 
radiation in polystyrene slide flasks (a) which were aligned and fixed in position (b) for 
irradiation with antiprotons. Schematic shows one sample holder as an example only. In the 






Comparison of this year’s controls with last year  
 
Control samples displayed very low levels of DNA damage. Mean number 
foci from scoring of two independent samples of 200 cells was 1.7 as also 
measured under standard cell culture conditions in our laboratory in Belfast. Mean 
number foci per nucleus in the 2008 control was 13 (fig.12). Availability of sterile 
cell culture facilities, as well as the new experimental design for this year has 
ensured that not a single sample was contaminated despite being completely 
submerged in the water phantom for irradiations. 
a) b) 






Fig.12. Non-irradiated control samples. (a) Foci score indicates level of endogenous DNA damage 
significantly decreased in control samples this year relative to last year’s samples. Error bars also decreased 
substantially. Medians for warm and cold controls were not significantly different. Error bars indicate SEM. 
(b) Low levels of endogenous γ-H2AX foci in controls shown by immunofluorescence for 2009 samples. 
 
Analysis of immediate DNA damage response to antiproton irradiation:  
γ-H2AX assay 
 
Response to direct irradiation 
Foci were scored in cells across the diameter of a 6mm spot on the sample 
slides which was positioned according to the gaf chromic film on each sample. All 
plateau samples contained many cells with bright and well defined foci. The mean 
number of foci in plateau samples was observed to be dose responsive. SOBP 
samples contained many cells which displayed very dense or clustered DNA 
double strand breaks (observed at x63 magnification) (fig.13b). Plateau samples 
did not show similar clustered foci regardless of dose or total number of foci 
(fig.13b). This indicates complex DNA damage caused by the antiproton 
annihilation. Number of foci per cell is also dose dependent in the SOBP. The 
experimental set up allowed two samples to be placed back to back (cell 
monolayers ~ 3mm apart) in the SOBP.  
In addition to scoring the effects of direct irradiation, distant response 
perpendicular to the beam has also been recorded at 3mm increments away from 
the edge of the beam (assuming diameter of 6mm). At 3mm mean foci number 
drops dramatically and by 18mm the level of damage is similar to that in the 
controls (fig.13b). This trend will be analysed against the dose response measured 
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Fig.13. DNA damage dose response to antiproton SOBP and plateau. A) Mean number of foci per nucleus 
(200 nuclei per sample) increases with dose. B) Immunofluorescence images representative of foci 
distribution in 2Gy samples in SOBP and plateau. ‘Direct’ indicates cells that were placed in the beam path 
while ‘Indirect’ indicates cells within the same sample that were out of the beam path (not traversed by 
antiprotons). The mean foci number in these regions was similar to that of the control samples. Non-irradiated 
controls were otherwise treated same as irradiated samples. Red arrows indicate nuclei with clustered foci. 
 
Indirect effects of antiproton irradiation 
 
Scoring of γ-H2AX foci in bystander samples revealed a modest increase in 
DNA damage relative to the control samples. This effect does not, however, 
appear to be dose dependent. These cells were incubated with culture media from 
samples that were irradiated with antiprotons in the SOBP.  
Analysis of secondary particle samples that were placed in the phantom at the 
time of irradiation and fixed adjacent to the directly irradiated samples display no 
significant increase in damage relative to the controls at this time. A strong 
response was not expected at the distances measured due to the relatively low 
dose of secondary particles, which drops off quickly with distance from the 
annihilation vertex. Only cells adjacent to the 2Gy sample gave a response that 
was significantly different to the controls. The data seem to indicate a dose 
dependent response; this will be confirmed with data from 5Gy samples, which 

















Fig.14. For each dose there are five sample sets for the γ-H2AX assay, each of which provides different 
information about the effects of either direct or indirect antiproton irradiation. Two sample were placed in the 
Bragg peak for each dose-labeled here as ‘f.SOBP’ and ‘b.SOBP’ (f: front, b: back) where f was the sample 
closer to the plateau. Mean foci number for f.SOBP and b.SOBP was only significantly different in the 0.5Gy 
dose samples, P<0.001). Results are for one experiment; error bars are SEM for 200 cells per sample. ’***’ 
indicates P value of less than 0.001, ‘*’ indicates P value less than 0.05. 
 
Analysis of longer term damage: Micronucleus assay 
 
In non-irradiated control samples binucleated cells (BN) were counted within 
a sample spot of 6mm diameter. The percentage of BN in the control population 
was ~40%. Using this assay micronucleated cells (MN) are usually scored from 
1000 BN. This was not possible here due to the small sampling radius.  
Previous experiments using this assay for the AGO1522B cell line have 
demonstrated similar or lower binucleation in non-irradiated control samples. A 
repeat of these experiments with X-rays is planned following the same protocols 
as for antiproton experiments. Initial data suggests that the impact on cell survival 
is strongly linked to radiation quality. 
The level of binucleation provides only information on the potential for cell 
survival. Of more importance for these experiments are those cells which survived 
antiproton irradiation and display evidence of genetic instability. Our data suggest 
that loss of genetic integrity is dose dependent for SOBP irradiation. Analysis of a 
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5Gy SOBP-irradiated sample is anticipated to show a complete loss of 
binucleation. 
More interesting will be the MN induction in the plateau as there little cell 
killing is expected. Ultimately it will be the sub-lethal damage in the entrance 




1. Genetic instability 
Up to now evidence from investigations into antiproton induced cell damage 
has indicated that exposed cells experience either lethal or non-lethal damage, 
where lethality is linked strongly to radiation LET. We are interested to know 
with what frequency there is genetic instability in cells that survive an antiproton 
dose.  
It has been shown that antiproton traversal in the plateau dose result in 
elevated DNA damage and that impact for bystander signaling and secondary 
particles near the SOBP induces a level of damage above that of the control. 
Clonogenic survival data (at least in V79 cells) would indicate that damage 
expressed in the plateau region is non-lethal. The next question then is how 
successfully the non-lethal damage is repaired and at what rate genetic instability 
is created in the original cells and to what extent this is transmitted in their 
progeny. 
 
2. Effectiveness of antiproton SOBP in hypoxic cells 
It has been proposed that the high LET antiproton Bragg peak would 
potentially increase cell killing ability in hypoxic tissues. We would like to test 
this hypothesis in a cell model under hypoxia. 
 
Note: A full report on the experiment is attached as Appendix II. 
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An important measure of the radiation quality for cancer therapy is the relative 
biological efficiency. Aside from a number of biological parameters like tissue 
type and cell environment amongst others, and physical parameters like dose and 
dose rate, RBE depends strongly on linear energy transfer (LET) or ionisation 
density. Weakly ionizing particles like x-rays have by definition an RBE value of 
1. Protons are also considered weakly ionizing (except for the very distal edge of 
the Bragg peak) and typically, for clinical use, are assigned an RBE value of 1.1 
throughout the entire path up to end of range. This is markedly different for heavy 
ions and antiprotons. Carbon ions, for example, are densely ionizing and have an 
RBE value that slowly increases from the entrance channel to the Bragg peak. In 
the case of antiprotons, our initial data indicate that the RBE value is close to the 
proton value along the main portion of the flight path in the target up to the very 
beginning of the Bragg peak with a relatively sudden increase to high RBE values 
at that point. For proper dose planning in heavy ion therapy and possible future 
use of antiprotons it is of great importance to gain more accurate knowledge of 
LET. The aim of our studies with the liquid ionization chambers (LICs) in the 
antiproton beam is to determine LET and ionization density along the beam path, 
and to compare these parameters with the results from protons and heavy ions.  
The ultimate goal is to develop general measurement methods and protocols to 
experimentally determine LET, which is closely related to RBE, at any given 
depth in the target. 
The most commonly used detector for precision dosimetry in clinical beams is 
the air filled ionization chamber. Their use is simple and methods for dosimetry 
have been developed over several decades and are now generally summarized in 
so called "dosimetry protocols" [17]. 
Ionization chambers having a liquid rather than air as their sensitive media 
offer some advantages in dosimetry. These advantages include high sensitivity 
which allows the chambers to be manufactured with small geometrical 
dimensions, making them suitable for measurements in beams with steep 
gradients. The high sensitivity is also a clear advantage in beams with low dose 
rate. In addition, it is known that commonly used liquid ionization chambers have 
minimal field perturbing effects [18]. 
These advantages come at the cost of some drawbacks, such as leakage current 
and dependency on radiation quality and dose rate. The leakage current is not a 
serious drawback in clinical accelerator beams due to the high output from 
accelerators, but may be disturbing in low dose rate applications. 
The dose rate dependence in the liquid ionization chamber response is caused 
by general recombination losses, in which case ions created by different incoming 
ionizing particles interact within the liquid volume and the net charge of the 
interacting species is reduced.  
In addition to general recombination processes, initial recombination in liquid 
ionization chambers is substantial. The high degree of recombination losses, both 
general and initial, is caused by the relatively high density of the liquid (at least 
when compared to air) resulting in high ionization density in the liquid. This in 
combination with low ion mobility results in a pronounced recombination.  
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Initial recombination, i.e. when ions created by the same incident ionizing 
particle recombine, is clearly dependent on the ionization density along the 
incident particle. This process is often also referred to as columnar recombination. 
This means that initial recombination is a measure of the energy transferred 
"locally" from the incident particle to the medium. This offers the possibility to 
relate the initial recombination losses to the Linear Energy Transfer (LET) of the 
beam. The aim of the present measurements with liquid ionization chambers 
(LICs) in the antiproton beam is precisely this; to study initial recombination 
losses and relate it to LET. 
 
2. Materials 
Two new liquid ionization chambers from PTW, Germany, have been 
purchased for LET experiments. The chambers have identical radii of 1.25mm and 
electrode spacing of 0.35mm. One of the chambers was filled with a non-polar 
liquid, isooctane (C8H18, Merck, isooctane analysis grade, 99.5% purity) and the 
other chamber was filled with non-polar Tetramethylsilane (TMS, Si(CH3)4, 
Merck, NMR calibration grade, 99.7% purity). Both chambers are water tight. 
The chambers were connected to a Keithley High Voltage Power supply, 
model 248, which is able to provide voltages up to 5000V. A Keithley 6517A 
programmable electrometer was used to read the charge collected from the 
ionization chambers. Both the power supply and the electrometer were controlled 
by a dedicated LabView program. 
 
3. Methods 
All measurements with the liquid ionization chambers were made in a water 
phantom. A large plane parallel air filled ionization chamber was mounted to the 
entrance of the phantom and used for monitoring shot-to-shot beam fluctuations 
[19].  
 
3.1 Isooctane chamber 
With the Isooctane chamber, measurements were made in the plateau region 
(10 mm depth), at the Bragg peak (100 mm depth) and at depths 2mm and 5mm 
beyond the distal edge of the Bragg peak. The applied voltages ranged from 100V 
up to 900V in steps of 100V and at each voltage 10 measurements were made. 
Occasionally, when measurements at a certain depth were repeated, the applied 
voltages ranged from 100V or 300V up to 900V in steps of 200V.  
 
3.2 TMS chamber 
With this chamber measurements were carried out in the plateau region and at 
the Bragg peak and at 2mm depth beyond the Bragg peak. The voltage range was 
the same as with the Isooctane chamber. 
 
4. Summary of theory for columnar recombination 
As mentioned in the Introduction, the aim of the liquid ionization chamber 
experiments is to determine the LET at different depths in water in the antiproton 
beam. This is done by studying columnar recombination losses in the chamber.  
Jaffé [20] has developed a theory for columnar recombination and this theory 
is so far used in the present work. The theory is based on the assumption that the 
charge density (charge per unit volume) changes in the volume through diffusion 
and by recombination. According to Jaffé theory, the situation in liquids is 
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particularly simple since diffusion can be neglected in comparison with 
recombination losses [20,21].  
The charge density change per unit time is therefore given by 
 
  (1) 
 
where  is the charge of one sign per unit volume,  the recombination 
coefficient and e the elementary charge.  
Recombination losses can take place as long as ions of opposite sign occupy 
the same volume along an incident particle. The resulting recombination losses is 




with , and where  is the recombination coefficient, and k1 
and k2 are the mobilities of the positive and negative ions,   is the initial charge 
per unit volume created by one proton, h is the thickness of the liquid layer 
(0.35mm) and U is the applied voltage.  
Omitting the details of the calculations, the relative LET at depth z is 
determined from the relation 
 
  (3) 
where  is the fluence averaged LET at the depth z in water in the antiproton 
beam,  the charge created per spill by the antiprotons and  is the 
antiproton fluence at the depth z in water. The reference depth, z0, was taken at 
10mm depth in water.  
It is obvious that the LET values we are able to determine currently are 
relative ones. This, however, is not a serious drawback since the LET at the 
reference depth is easily calculated from stopping power values.  
The fluence ratio, , was calculated with the FLUKA Monte-Carlo 
code. 
 
5. Correction for general recombination 
Since the dose per spill is high in the antiproton beam, substantial general 
recombination losses are present in the liquid ionization chambers. The most 
widely used theory for correcting for general recombination loss is that due to 
Boag [22]. The theory's validity for liquid ionization chambers has been tested for 
dose per pulse in the range 0.06mGy/pulse up to 1.9mGy/pulse [18]. Since the 
dose per spill in the antiproton beam is much higher than the "clinical" values 
used by Johansson et al, a direct application of Boag's theory cannot be 
unquestionable and needs to be tested in more detail. It should be noted though, 
that using Boag’s theory for our beam conditions led to excellent agreement 
AD-4 Status Report 2010 
24 
between measurements and Monte Carlo calculations for air filled ionization 
chambers [19].  
 
6. Results and discussion 
 
Figure 15 shows the results obtained with the Isooctane chamber. Using 
equation (3) for LET determination, the LET at the Bragg peak is calculated to be 
9.0keV/µm. This value should be compared to 3.2keV/µm in the Bragg peak of a 
173MeV proton beam determined with the same method. Kempe et al. [23] used 
the Monte-Carlo code Shield-HIT and calculated the fluence averaged LET in the 
Bragg peak to 3.63keV/µm in a 202MeV proton beam. The LET in the Bragg 
peak determined with the TMS chamber is 10.0keV/µm.  
 
Since there is currently a high uncertainty in the correction for general 




Figure 15. Charge measured at different applied voltage using a ionization chamber filled with Isooctane. The 
experimental values are fitted to the Jaffé theory. 
 
 
7. Future work 
 
The most important work to do in this subject is to determine the general 
recombination losses in a pulsed beam.  
At the Dept. of Radiation Sciences, Radiation Physics, Umeå University, we 
are currently testing the Boag theory for liquid ionization chambers at high dose 
per pulse. The experiments are planned to be completed at the beginning of 2010. 
The experiments are done using a race-track microtron with a swept and pulsed 
beam. By stopping the sweep the dose per pulse is increased to much higher 
values than the values for which Boag's theory has been tested [18].  
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We expect that future experiments will cast some more light onto the validity 
of equation (3). The results presented in this section must therefore be considered 
as preliminary. 
 
V. Real-time Imaging of the Antiproton Annihilation Distribution 
 
Real real-time monitoring of the stopping distribution of particle beams used 
for radiotherapy provides the possibility of detecting possible errors in dose 
deposition early during a given treatment session, and may therefore help to 
improve the quality of the therapy. Imaging of 511 keV gammas from positron 
emitting isotopes generated in the target (in the case of proton therapy) or the 
beam (for carbon ions) have been studied for this purpose, and in-situ PET 
imaging for carbon ion therapy was an integral part of the therapy at GSI. 
Unfortunately, the lifetime of PET isotopes does not allow for a true real-time 
imaging and this method has been used mostly to confirm the correct dose 
delivery after a given treatment. Furthermore, there is no direct one-to-one 
relationship between the PET activity distribution and the dose distribution. More 
recently a development has been initiated to detect the prompt gammas from 
nuclear reactions with the target in proton therapy, which then can be correlated 
with the range distribution of primary particles.  
Antiproton annihilation events produce several long-range secondary particles 
which can be detected in real time by standard high energy particle physics 
detector systems. We have performed Monte Carlo calculations [24] in order to 
study the feasibility of real-time imaging by detecting charged pions produced 
during antiproton irradiation of typical biological targets. A simple treatment plan 
in a water phantom is simulated and the results show that by detecting charged 
pions the position and the size of the planned target volume can be located with a 
precision on the order of 1-2 mm. Figure 16 shows the calculated dose distribution 
and differential antiproton fluence together with the vertex distribution detected 
with the virtual detector. The number of particles used in the calculation was 1 
million, which is significantly less than 1% of the particles needed to deposit a 2 




Fig. 16: Comparison of the physical dose (open circles) and the vertex position (crosses) along the beam axis 
(left panel) and perpendicular to the beam direction (right panel). In the left panel we also show the 
differential antiproton fluence. 
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To realize such a detection system with a minimal requirement on detection 
equipment we proposed, and performed first tests, of a novel arrangement. Instead 
of several layers of large size silicon pixel detectors facing the expected vertex 
distribution we propose to use a single area pixel detector rotated by 90 degrees, 
facing the vertex distribution edge on. This would lead to grazing incidence of 
particles from the annihilation vertex, leaving long tracks spanning several 
neighboring pixels. To test this concept we collaborated with the Petra Riedler and 
her colleagues from the ALICE Silicon Pixel Detector team from whom we were 
provided with one (spare) ladder consisting of 10 chips from the Alice detector, 
including control and read-out electronics. The detector is 13.6 cm long, 1.3 cm 
wide and 200 µm thick and consists of 320 columns of 425 µm width and 256 





Fig. 17: Layout of the ALICE pixel detector used for the real-time imaging tests 
 
For our tests we set up the detector with the 13 cm x 200 µm area facing the 
expected Bragg peak location (see figure 18). To cope with the high instantaneous 
annihilation rate of 3 x 107 antiproton annihilation in a 500 ns pulse the distance 
between the detector and the beam axis was chosen at 1.5 meters. 
 
 
Fig 18: Arrangement of detector for real-time imaging tests at AD-4 
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When rotating the detector in ½ degree steps we can sweep across the spread-





Fig. 19: Tracks detected from a single antiproton shot stopping in a water phantom 1.5 meters away from the 
detector. Shown are both the full detector ladder and a partial zoom to a smaller area. One can clearly see a 
difference in track length distribution for the two cases shown; left: facing at the Bragg peak, right: pointing 
towards the distal region. 
 
We are currently in the process of optimizing a track recognition algorithm to 
automatically detect tracks as well as their direction and length. We also have set 
up the detector, phantom, and antiproton beam in FLUKA and are studying the 
optimal positioning of the detector with respect to the beam direction in terms of 
spatial resolution. Based on these results we plan to perform one additional data 
run from which we then will construct the axial distribution of annihilation 
vertices as a proof of principle of the method.  
 
VI. Beam Monitor for Particle Therapy Application 
 
In particle therapy in general and in our experiment in particular there is a 
strong need for a fast, high precision, 2 dimensional, well characterized beam 
monitor. Up to now we have used a fast transformer beam current monitor (BCM) 
from Bergoz Instrumentation to determine the integrated intensity for a single 
pulse. For the lateral position and shape of the beam pulse we use as a standard 
means Gafchromic Films, which have been widely used in particle beam therapy, 
as well as a scintillating screen, imaged with an intensified CCD camera. The 
films are used to integrate the overall exposure for a given irradiation period, but 
can not be used for single shot monitoring. The scintillator-camera combination 
was yielding good results at 50 MeV, but since the energy deposition of the 126 
MeV beam is lower, the intensity is no longer sufficient to obtain a high resolution 
image from a single pulse. 
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We have therefore started a collaboration with the group of M. Caccia from 
the University of Insubria in Como to test the Mimotera Detector for our 
application. Mimotera is a Monolithic Active Pixel Sensor (MAPS) consisting of 
an array of 112 x 122 pixels of 153 µm x 153 µm each. The pixel arrays are 
subdivided into two interleaved sub-arrays, which are read out alternating to 
eliminate any dead time. 
Initial tests performed during the 2009 beam time showed promising results 
and we are now developing a dedicated beam monitoring system for AD-4 based 
on the Mimotera design. Aside from using it as a beam position and beam shape 
monitor and as an alignment tool for the experiment we also will study the 
response of the detector to varying dose rate and LET in order to quantify the 
detector response for hadron therapy in general. In figure 20 we show a 




Fig. 20: Images from single antiproton shot. Clockwise from top left: 2D image of beam shape, 3D lego 
representation of beam intensity distribution, x and y radial distributions for 6 individual shots, showing small 
shot-to-shot variations.   
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VI. Summary, Outlook, and Beam Time 
 
Using a total of less than six weeks of beam time over the last 7 years we have 
now reached the point where we have developed reliable tools for physical 
dosimetry and beam delivery planning. This has allowed us to collect an initial 
data set on the relative biological efficiency (RBE) of antiprotons for the chosen 
endpoint of 10% clonogenic survival of V-79 Chinese Hamster cells. Our current 
results are in agreement with the first measurements using a 50 MeV beam, where 
we measured a Biological Effective Dose Ratio (peak-to-plateau) four times larger 
for antiprotons than for protons. We observe a steep increase of RBE for 
antiprotons at the proximal edge of a spread-out Bragg peak (SOBP), in contrast 
to carbon ions, where RBE is increasing gradually along the beam path. Using a 
simplified model for RBE variation along the beam for both antiprotons and 
carbon ions, a step-function going from 1 to 2 only for the Bragg peak, we 
performed a dose planning study for a cubic target of 2x2x2 cm3 dimension. 
Using the resulting dose volume histograms (DVH) we can identify certain 
advantages and disadvantages of the different particle modalities. 
To quantify these findings and apply them to specific tumor incidents, 
believed to be prime candidates for a future antiproton therapy application, we 
have to confirm our current data and achieve a higher statistical significance by 
performing a number of independent repeat experiments. We also need to 
accumulate more data points for each depth slice in the target in order to obtain 
higher quality fits to the currently sparse data set. The dose planning studies need 
to be expanded by including the actual variation of RBE with depth for both 
carbon ions and antiprotons. And last-but-not-least, the optimization of the dose 
plan used for the different modalities needs to be improved. 
In addition to RBE in the target area for clonogenic survival an equally, if not 
more important, question we have started to address is the effect of DNA damage 
and genetic mutation, and the relation to possible tumorigenesis. Such late effects 
are an active topic of discussions in all radiotherapy modalities and we expect 
more physical and biological studies in this field to become available in the next 
years. 
As a support of these biological studies we have initiated developments on 
dosimetric tools for mixed radiation fields and have benchmarked our preferred 
Monte Carlo code (FLUKA) against experimental data. We have shown the 
possibilities for absolute dosimetry using Alanine pellets and linear energy 
transfer (LET) measurements using liquid ionization chambers. To improve our 
data taking capability at the AD we have identified novel beam monitors and are 
in the process of upgrading our experimental set-up. 
One unique opportunity offered by antiprotons is the immediate, in principle 
particle-by-particle, detection of the annihilation vertex, and therefore dose 
distribution, in 3D. Monte Carlo studies have shown that a small percentage of the 
dose delivered during a treatment fraction would be sufficient to obtain a dose 
distribution confirmation within the range of a few percent. To experimentally 
realize this possibility we have performed first tests using one sample ladder of 
the ALICE silicon pixel detector. By setting it up in a geometry where secondary 
pions and gammas from the annihilation would have a grazing incidence, 
generating tracks across a large number of adjacent pixels, we have shown a 
dependency of track length on the angle between the detector orientation and the 
direction of incidence of the pions or gammas. We are now studying the 
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possibilities to expand this into a 3D reconstruction of vertex distribution with 
minimum detector requirements. 
With the limited data set we have been able to accumulate in the few weeks of 
beam time since inception we have now reached a point where many of the initial 
questions have been addressed and a potential of a future use of antiprotons in 
cancer therapy can be argued. We now need to improve the statistical quality of 
the dataset to apply our knowledge to comparative dose planning exercises on 
specific, clinical relevant, tumor incidents. 
To allow us to move forward in this research efficiently we request a 
continuation of the current procedure, where one week of AD beam time at 500 
MeV/c is dedicated to our experiment. This week would be split between the 
continuation of clonogenic survival measurements, DNA damage studies, and the 
development of LET measurements with Liquid Ionization Chambers (LIC). 
Considering the 26 weeks of AD Physics time available in 2009, this is less than 
5% of the total beam available, far less than the initial threshold of 10% discussed 
at the outset of AD-4. To set the amount of beam time in perspective: the overall 
number of antiprotons delivered to AD-4 since inception is equivalent to just a 
few hours of beam time at a carbon ion therapy facility.  
To speed up progress and allow students to finish their thesis work in a timely 
manner we ask for 7 additional eight-hour shifts of 5 MeV beam into the AD-4 
zone. This beam can be beneficially used for detector development, real time 
imaging studies, and tests of liquid ionization chambers and solid-state detectors 
in the high LET regime near the end of range. This would free up valuable beam 
time for the biological studies during the 500 MeV/c run week. Ideally we would 
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Analysis of Antiproton induced DNA damage: non-targeted effects of radiation.  




Radiotherapy employs ionizing radiation (IR) to cause lethal damage to cells. It is widely accepted that 
cellular DNA is the most critical target. Immediately following an insult on DNA, damage sensing proteins 
(e.g. 53BP1, ATM) are recruited to the site of damage.  This signals cell cycle arrest so that DNA repair can 
take place (Bryant, 1985; Bonner et al, 1998). If the damage is too extensive to be repaired programmed 
cell death (apoptosis) will be initiated. Damaged cells which are also deficient in cell cycle check point 
proteins may not arrest and enter mitosis. The result is mitotic catastrophe, a common phenotype of which 
is enlarged cells containing multiple micronuclei. Following a mitotic catastrophe, cells may continue to 
cycle for a short time but are not viable long term as they lack significant genetic information, and will 
ultimately undergo cell death. This type of damage-induced response, called mitotic cell death, can be a 
mechanism by which cells prevents aneuploidization which can lead to tumorigenesis (Castedo, 2004; Molz 
et al 1989).  
In addition to direct damage from IR, there is mounting evidence for the existence of a non-targeted effect 
in which non-irradiated cells respond to the damage of their neighbours. This effect is know as the radiation 
induced bystander effect (RIBE) and it has been demonstrated in vitro for a number of endpoints including 
clonogenic survival, histone H2AX phosphorylation (γ-H2AX) and genetic instability. There are also a 
number of in vivo studies showing these effects in mice. It is likely that RIBEs may contribute to the 
clinical appearance of abscopal effects post radiotherapy (Mothersill,1998; Seymour,2000; Mancuso,2008). 
The aim of this study was to quantify the individual contributions of antiproton annihilation, secondary 
dose (neutrons, pions etc) and bystander signalling caused in live cells exposed to an antiproton beam. The 
study has a particular focus on the impact outside of the target volume in terms of cell viability and 
genomic integrity. The γ-H2AX and micronucleus assays have been used to study immediate and longer 
term DNA damage respectively. A pilot study at CERN in October 2008 demonstrated the applicability of 
this type of assay to studying antiproton induced DNA damage. These early experiments highlighted a 
number of issues: dose rate effects; contamination; the importance of cell culture facilities at or near CERN 
to obtain significant information from the samples. (Problems highlighted in last year’s report.) Each of 
these issues has been addressed in the design of experiments for the 2009 beam time. Significant changes 
were made to the experimental set-up to minimise possibility of leaking or infections in the cell culture. In 
addition Oliver Hartley, at Geneva Medical University opened his lab to our group so that tissue culture 
could be carried out under sterile conditions within a short time before each experiment. This helped 
minimizing stress due to external factors as confirmed by a normal background level of damage in controls.  
Finally, modifications to experimental design allowed us to compensate for effects of dose rate on the DNA 
damage assays used. 
In addition to cell experiments, the plasmid DNA assay was revisited to trial an optimised protocol which 
has previously demonstrated increased sensitivity to clinically relevant radiation doses (Wyer et al 2009; 
Folkard, 1999). 
Materials and Methods 
Cell Culture 
AGO1522 human fibroblast cells were cultured in filtered alpha-MEM (LONZA, BioWhittaker®) 
supplemented with foetal bovine serum (15%), penicillin (100 IU/ml) and streptomycin (100 µg/ml) and 
Hepes buffer (25 mM) in a 95% air/5%CO2 37oC atmosphere. 10 h prior to treatment, cells were detached 
from culture flasks and were seeded in polystyrene slide flasks (NUNC) in 2 ml alpha-MEM and incubated 
(fig.1a). For γ-H2AX assay ~6 × 105 cells seeded and for micronucleus assay ~ 3 × 104 cells seeded per 
sample. 2-3 h prior to irradiation sample flasks were filled with cold supplemented alpha-MEM 
(eliminating as much air as possible) and flasks were sealed closed. Samples transported to CERN in 
Appendix II
  
insulated container maintaining temperature at ~4ºC. Cell samples were kept cold for a maximum of 12 h. 




Slide flasks containing cell samples were mounted within a phantom in specially designed holders. These 
were positioned at depths of 20 mm (plateau) and 101 mm (centre of SOBP) (fig.1b). Cell samples were 
irradiated horizontally in an open water phantom with circulating water-glycerine mixture maintained at 4 
ºC. Cells received estimated Bragg peak doses of 0.5, 0.75, 1.0, 2.0 and 5.0 Gy antiprotons. In addition to 
irradiated samples there were three sets of unirradiated samples: 1) bystander cells (otherwise treated same 
as irradiated cells) were incubated at 37 ºC for 1 h with filtered media from SOBP directly irradiated 
sample, 2) cold controls which were otherwise treated the same as irradiated samples, 3) warm controls 
which remained incubating at 37 ºC in the lab and were fixed along with the other samples. This third set 























Fig.1. Experimental set-up for DNA damage experiments in 2009. Cells were seeded for radiation in polystyrene slide flasks (a) 
which were aligned and fixed in position (b) for irradiation with antiprotons. Schematic shows one sample holder as an example 
only. In the SOBP two flasks were fixed back-to-back as shown, cell monolayers separated by 3mm within the SOBP. 
 
Post radiation treatment 
Each set of samples were warmed to 37oC simultaneously for 1 h in a 95% air/5% CO2 atmosphere. A time 
course of development of γ-H2AX foci following cold irradiation of this cell line had previously been 
established with X-rays in Belfast. All cells were incubated for 1 h post irradiation to allow accumulation of 
DNA damage sensing proteins. All samples were fixed in ice-cold methanol/acetone (1:1) for 10 min. The 
fixed cells were washed once in PBS and stored in fresh sterile PBS for transportation to Belfast.  
γ-H2AX assay 1) Directly or secondary particle irradiated samples were fixed after 1h incubation. 2) 
Bystander samples were incubated for 1h with filtered culture media removed from directly irradiated 
samples. These samples were then also fixed.  
Cells were permeablized with 0.5% Triton®X-100 (Sigma-Aldrich) solution in PBS for 20 min at 4ºC; non-
specific binding was blocked with 0.2% skimmed milk, 5% foetal bovine serum and 0.1% Triton®X-100 in 
PBS for 1 h at 4ºC. Cells were incubated for 1 h at 20ºC with anti-phospho-H2AX (mouse monoclonal 
a) b) 
  
antibody, clone JBW301, Upstate Biotechnology). Cells were washed in 0.1% Triton®X-100 solution and 
then incubated for 1 h at 4ºC with Alexa Fluor® 488 goat anti-mouse cross absorbed antibody (Molecular 
Probes). Total nuclear DNA was stained with Hoechst stain. Slides were treated with Vectashield mounting 
media (Vector Labs) and covered with glass cover slips. Images were captured using a Zeiss camera. For 
directly irradiated samples, cell nuclei were scored only in the centre of the cover slip to ensure all cells 
within a scored sample had received uniform dose. Images of the cells show the nuclei stained blue and 
DNA damage (foci) shows up as bright green spots within the nuclei. 
 
Micronucleus assay 1) Directly or secondary particle irradiated samples were treated with cytochalasin-B 
(0.5µg/ml, Sigma) after 1 h incubation. These were incubated for a further 36 h (time at which maximum 
number of binucleated cells is seen in this cell line for this assay) prior to fixing. 2) Bystander cells were 
incubated for 1h with filtered culture media removed from directly irradiated samples prior to addition of 
cytochalasin B. The fixed cells were washed once in PBS and stored in fresh sterile PBS for transportation 
to Belfast. 
Cells were stained with Acridine orange (Sigma, 25 µl/ml) for 20 min. Washed with fresh PBS x5. Total 
nuclear DNA was stained with Hoechst stain. Samples were mounted and imaged as for γ-H2AX assay.  
The numbers of binucleated cells and binucleated cells which had micronuclei were scored within the beam 
diameter (as determined with gaf chromic film) and outside of the beam. 
 
Plasmid DNA  
The plasmid, pcDNA3.1 (Invitrogen, Paisley, UK) was prepared by transformation of a 1 µl aliquot into 
competent Escherichia coli DH5α. A single colony, resulting from this transformation, was picked and 
grown by shaking overnight at 37°C in 10 ml of LB media supplemented with ampicillin (250 µg/ml). 
Plasmid was prepared from these cells using a Qiagen Maxi kit according to the manufacturer’s 
instructions. To remove buffer salts (e.g. Tris.HCl) which have previously been shown to scavenge radicals 
and thus reduce the amount of damage observed. DNA was desalted by using a spin column (Millipore). 
 
Two samples (each approximately 30 μl at a concentration of 450 ng.μl-1) of desalted plasmid solution were 
exposed to antiprotons (or mock irradiated). The estimated dose received by these samples was 5 Gy and 0 
Gy respectively. 
A 1 μl aliquot of each irradiated sample was mixed with 5 μl of deionised water and 1 μl of gel loading 
buffer (0.25% (w/v) bromophenol blue, 40% (w/v) sucrose) and resolved by electrophoresis on a 1%(w/v) 
agarose:TAE (40 mM Tris-acetate, 1 mM EDTA, pH 8.3) gel containing 0.002%(w/v) ethidium bromide.   
For comparison, a sample containing 450ng of unirradiated plasmid was electrophoresed alongside the 
experimental sample.  Electrophoresis was carried out in TAE buffer at 100 V (constant voltage) for 40 min 
and gels imaged using a ChemiDoc XRS gel imager (Biorad, Hercules, CA, USA). 
Statistical analysis 
Non parametric tests were carried out on data sets with non-Gaussian distributions. Cold and warm control 
sets (fig.3) were analyzed with the Mann-Whitney U test. Data medians of treated sample sets were initially 
compared with Kruskal-Wallis non-parametric test, individual median values were compared using Dunn’s 
multiple comparison test. 
 
Results 
1. 2008 beam time 
Human fibroblast cells were irradiated with antiprotons at 37°C positioned in plateau and SOBP of the 
Bragg curve for each dose given. Post irradiation cells were fixed, stained and nuclear DNA damage was 
scored. Control samples expressed unusually high levels of stress, ~13 foci per nucleus. (fig.2). The mean 
number of DNA DSBs was observed to increase approximately linearly with dose in the SOBP while the 
mean number of DSBs observed in the plateau was ~50% of the damage induced in the corresponding 
SOBP sample. Quantification of secondary particle effects and of bystander effects were not possible as 
these are expected to be very small effects and require higher sample number and more stringent controls 
  
for increases in DNA damage to be detected. Foci scoring of these samples was carried out and revealed an 
elevation in damage above that of the control although the error bars were very large as scoring was 











Fig.2. DNA damage increases with antiproton dose in SOBP. Mean number of foci, counted per cell over 50 cells per sample, 
increased approximately linearly with dose. Error bars indicated SEM of one sample. 
2. 2009 beam time 
Comparison of this years controls with last years  
Control samples displayed very low levels of DNA damage. Mean number foci from scoring of two 
independent samples of 200 cells was 1.7 as also measured under standard cell culture conditions in our 
laboratory in Belfast. Mean number foci per nucleus in the 2008 control was 13 (fig.3). Availability of 
sterile cell culture facilities, as well as the new experimental design,  this year has also ensured that not a 











Fig.3. Non-irradiated control samples. A) Foci score indicates level of endogenous DNA damage significantly decreased in 
control samples this year relative to last years samples and error bars decreased. Medians for warm and cold controls were not 
significantly different. Error bars indicate SEM. B) Low levels of endogenous γ-H2AX foci in controls shown by 
immunofluorescence. 
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Analysis of immediate DNA damage response to antiproton irradiation: γ-H2AX assay 
a) Response to direct irradiation 
Foci were scored in cells across the diameter of a 6mm spot on the sample slides which was positioned 
according to the gaf chromic film on each sample. All plateau samples contained many cells with bright and 
well defined foci. The mean number of foci in plateau samples was observed to be dose responsive. SOBP 
samples contained many cells which displayed very dense or clustered DNA double strand breaks 
(observed at x63 magnification) (fig.4b). Plateau samples did not show similar clustered foci regardless of 
dose or total number of foci (fig.4b). This indicates complex DNA damage caused by the antiproton 
annihilation. Number of foci per cell is also dose dependent in the SOBP. The experimental set up allowed 
two samples to be placed back to back (cell monolayers ~ 3mm apart) in the SOBP. The scoring of foci 
revealed that only in the ‘0.5Gy’ samples was the difference in damage significant. This may be attributed 
to relatively uneven SOBP predicted for this low dose point. All other doses were given with a flat SOBP. 
In addition to scoring the effects of direct irradiation, distance response perpendicular to the beam has also 
been recorded at 3mm increments away from the edge of the beam (assuming diameter of 6mm). At 3mm 
mean foci number drops dramatically and by 18mm the level of damage is similar to that in the controls 

















Fig.4. DNA damage dose response to antiproton SOBP and plateau. A) Mean number of foci per nucleus (200 nuclei per sample) 
increases with dose. B) Immunofluorescence images representative of foci distribution in 2Gy samples in SOBP and plateau. 
‘Direct’ indicates cells which were placed in the beam path while ‘Indirect’ indicates cells within the same sample which were 
 Control 
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out of the beam path (not traversed by antiprotons). The mean foci number in these regions was similar to that of the control 
samples. Non-irradiated controls were otherwise treated same as irradiated samples. Red arrows indicate nuclei with clustered 
foci. 
Indirect effects of antiproton irradiation 
Scoring of γ-H2AX foci in bystander samples revealed a modest increase in DNA damage relative to the 
control samples. This effect does not, however, appear to be dose dependent (fig.5a). These cells were 
incubated with culture media from samples that were irradiated with antiprotons in the SOBP. It could be 
that concentration of cytokines in the transferred media was too low to produce a strong response in 
bystander cells which were a much larger population than that which was directly irradiated.  Further 
comparison with X-ray radiation is required to corroborate this analysis. 
Analysis of secondary particle samples (see fig.5b) which were placed in the phantom at the time of 
irradiation and fixed adjacent to the directly irradiated samples display no significant increase in damage 
relative to the controls at this time. A strong response was not expected at the distances measured due to the 
relatively low dose of secondary particles which drops off quickly with distance from the annihilation 
vertex. Only cells adjacent to the 2Gy sample gave a response that was significantly different to the 
controls. The data seem to indicate a dose dependent response; this will be confirmed with data from 5Gy 
















Fig.5. Indirect effects of antiproton radiation. A) Bystander experiment, results from two independent samples, error bars indicate 
standard deviation from the average of the two means;  B) secondary particle experiment, results from one experiment, error bars 




























































































Fig.6. For each dose there are five sample sets for the γ-H2AX assay each of which provides different information about the effects 
of either direct or indirect antiproton irradiation. Two sample were placed in the Bragg peak for each dose-labeled here as ‘f.SOBP’ 
and ‘b.SOBP’ (f: front, b: back) where f was the sample closer to the plateau. Mean foci number for f.SOBP and b.SOBP was only 










































































       0.5 0.75 2.0
























Analysis of longer term damage: Micronucleus assay 
In non-irradiated control samples binucleated cells (BN) were counted within a sample spot of 6mm 
diameter. The percentage of BN in the control population was ~40%. Using this assay micronucleated cells 
are usually scored from 1000 BN. This was not possible here due to the small sampling radius.  
In samples which received antiproton SOBP irradiation there is little if any evidence of cells attempting 
division. Samples which received antiproton SOBP irradiation had 8% and 5% BN for 1 and 2 Gy 
respectively (fig.7a). Of the BN present in each irradiated sample 39% and 68% had micronuclei, compared 









Fig.7. Micronuclei assay. A) Percentage of sample population with binucleated cells decreases with SOBP antiproton radiation. B) 









Fig.8. Immunofluorescence images of cells treated with cytochalasin B for 36h after antiproton treatment. 
 
Previous experiments using this assay for the AGO1522B cell line have demonstrated similar or lower 
binucleation in non-irradiated control samples. A repeat of these experiments with X-rays is planned 
following the same protocols as for antiproton experiments. Initial data suggests that the impact on cell 
survival is strongly linked to radiation quality. 
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The level of binucleation provides only information on the potential for cell survival. Of more importance 
for these experiments are those cells which survived antiproton irradiation and display evidence of genetic 
instability. Figure 7b suggests that loss of genetic integrity is dose dependent for SOBP irradiation. 
Analysis of a 5Gy SOBP-irradiated sample is anticipated to show a complete loss of binucleation. 
More interesting will be the MN induction in the plateau as there little cell killing is expected. Ultimately it 
will be the sub-lethal damage in the entrance channel which limits the outcome of any radiation treatment.  
 
Gaf chromic film 
Water resistant strips of gaf chromic film were attached to the back of directly irradiated sample flasks. The 
immediate purpose was orientation of the region of the samples that was directly in the beam path. The 
films can also provide some information on beam shape and dose deposition for the dose range in both 





















Fig.9. A scan of the gaf chromic film which had been attached to sample 31 at the time of antiproton irradiation was inverted and 
subsequent intensity profile plotted using Image J software package. 
 
Antiproton induced damage in plasmid DNA 
Desalted plasmid DNA received estimated antiproton SOBP dose of 5Gy. Non-irradiated control sample 
was run on gel alongside the treated sample. Alongside the markers (run in lane 1), control sample (lane2) 
contains mostly super coiled DNA and a small amount of open circle DNA. Irradiated sample (lane3) has 
lost all super coiled DNA (to the level detectable with this assay) and instead contains open circular and 
linear DNA. This pilot experiment indicates that our plasmid DNA preparation has sufficient sensitivity to 













Fig.9. Antiprotons cause plasmid DNA damage. A) Plasmid gel with ladder (lane 1) untreated plasmid is mostly of the super coiled 
form with small amount of open circular (lane 2) antiproton treated plasmid DNA is in the form linear (double strand breaks) and 
open circle (single strand breaks) with no super coiled DNA detectable (lane 3). 
 
Summary 
• Collaboration with O. Hartley at Geneva Medical University for use of biological facilities before and 
during the beam time contributed greatly to the successful completion of a large sample set for several 
different experiments. This has demonstrated the possibility for more complex biological experiments in the 
future aided by that collaboration. 
• Ratio of DNA damage in the peak compared to the plateau gives an indication of an antiproton RBE for 
DNA damage induction which could be compared to RBE obtained from cell survival data (although cell 
lines differ). 
• Data collection from both micronucleus and γ-H2AX assays are still on going and has already provided an 
indication of short and long term effects on cellular DNA. 
• Indirect effects measured are very small and these will require specific statistical analyses to determine their 
significance. 
• Irradiation of desalted plasmid DNA has demonstrated a response to clinically relevant doses which was not 
achieved during the beam time of 2007. As plasmid DNA gels can be quantified this success suggests a 
possible future dosimeter for particle radiation which may be developed in future beam times. 
 
Future Experiments 
1. Genetic instability 
 
Up to now evidence from investigations into antiproton induced cell damage has indicated that exposed 
cells experience either lethal or non lethal damage, where lethality is linked strongly to radiation LET.  
We are interested to know with what frequency there is genetic instability in cells which survive an 
antiproton dose.  
It has been shown that antiproton traversal in the plateau dose result in elevated DNA damage and that 
impact for Bystander signaling and secondary particles near the SOBP induces a level of damage above 
that of the control. Clonogenic survival data (at least in V79cells) would indicate that damage expressed 
in the plateau region is non-lethal. The next question then is how successfully the non-lethal damage is 
repaired and at what rate is genetic instability created in the original cells and to what extent is this  
transmitted in their progeny. 
 
2. Effectiveness of antiproton SOBP in hypoxic cells 
It has been proposed that the high LET  antiproton Bragg peak would potentially increase cell killing 
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